Skip to main content

Table 1 Baseline demographics and disease characteristic of the patients

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Characteristic Dose groups
A (0.6 mg) B (1.2 mg) C (1.8 mg) D (2.4 mg)
Age (years), median 54.00 56.50 46.50 58.00
Gender n (%)
 Female 0(0.00%) 2(33.33%) 4(66.67%) 3(50.00%)
 Male 3(100.00%) 4(66.67%) 2(33.33%) 3(50.00%)
Height (cm), Mean (SD) 171.33 (6.35) 167.17 (5.31) 163.67 (6.09) 169.00 (8.99)
Weight (kg), mean (SD) 70.67 (16.92) 72.17 (11.02) 67.67 (16.72) 72.08 (9.97)
BSA (cm2), Mean (SD) 1.82 (0.24) 1.80 (0.14) 1.70 (0.18) 1.82 (0.17)
ECOGa PFS n (%)
 0 1(33.33%) 2(33.33%) 1(16.67%) 1(16.67%)
 1 2(66.67%) 4(66.67%) 5(83.33%) 5(83.33%)
Histological type n (%)
 Squamous 1(33.33%) 1(16.67%) 0(0.00%) 0(0.00%)
 Adenocarcinoma 2(66.67%) 5(83.33%) 6(100.00%) 6(100.00%)
First-line chemotherapy with cisplatin/carboplatin-based combination
 No. of Cycles (SD) 5.33 (0.94) 6.67 (1.15) 4.87 (1.21) 5 (1.53)
 Reaction to Chemotherapy, PR/SDb 2/1 3/3 1/5 2/4
  1. aECOG Eastern Cooperative Oncology Group, PFS performance status
  2. bPR/SD Partial Response/Stable Disease